Immunex (Global rights to Leukine) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Immunex (Global rights to Leukine) General Information

Description

An immuno-stimulant drug. The immuno-stimulant drug is a man-made form of granulocyte-macrophage colony-stimulating factor used to help increase the number and function of white blood cells after bone marrow transplantation, in cases of bone marrow transplantation failure or engraftment delay, before and after peripheral blood stem cell transplantation and following induction chemotherapy in older patients with acute myelogenous leukemia.

Contact Information

Website
www.leukine.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Boston, MA
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Corporate Office
  • Boston, MA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunex (Global rights to Leukine) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Immunex (Global rights to Leukine)‘s full profile, request access.

Request a free trial

Immunex (Global rights to Leukine) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Immunex (Global rights to Leukine)‘s full profile, request access.

Request a free trial

Immunex (Global rights to Leukine) FAQs

  • Where is Immunex (Global rights to Leukine) headquartered?

    Immunex (Global rights to Leukine) is headquartered in Boston, MA.

  • What industry is Immunex (Global rights to Leukine) in?

    Immunex (Global rights to Leukine)’s primary industry is Buildings and Property.

  • Is Immunex (Global rights to Leukine) a private or public company?

    Immunex (Global rights to Leukine) is a Private company.

  • What is Immunex (Global rights to Leukine)’s current revenue?

    The current revenue for Immunex (Global rights to Leukine) is .

  • Who are Immunex (Global rights to Leukine)’s investors?

    Immunex and Sanofi have invested in Immunex (Global rights to Leukine).

  • When was Immunex (Global rights to Leukine) acquired?

    Immunex (Global rights to Leukine) was acquired on 01-Feb-2018.

  • Who acquired Immunex (Global rights to Leukine)?

    Immunex (Global rights to Leukine) was acquired by Partner Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process